(19)
(11) EP 3 883 547 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.03.2023 Bulletin 2023/11

(45) Mention of the grant of the patent:
21.12.2022 Bulletin 2022/51

(21) Application number: 21700361.5

(22) Date of filing: 05.01.2021
(51) International Patent Classification (IPC): 
A61K 9/10(2006.01)
A61K 31/352(2006.01)
 A61K 9/51(2006.01)
A61K 36/185(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/51; A61K 9/10; A61K 31/352; A61K 36/185
(86) International application number:
PCT/EP2021/050089
(87) International publication number:
WO 2021/140101 (15.07.2021 Gazette 2021/28)

(54)

PREPARATION AND USE OF CANNABIS NANO-FORMULATION

HERSTELLUNG UND VERWENDUNG VON CANNABIS-NANOFORMULIERUNG

PRÉPARATION ET UTILISATION DE NANO-FORMULATION DE CANNABIS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 06.01.2020 EP 20150397

(43) Date of publication of application:
29.09.2021 Bulletin 2021/39

(60) Divisional application:
22214594.8

(73) Proprietor: CannaXan GmbH
83627 Warngau (DE)

(72) Inventor:
  • BRAND, Werner
    83627 Warngau (DE)

(74) Representative: Maiwald GmbH 
Elisenhof Elisenstraße 3
80335 München
80335 München (DE)


(56) References cited: : 
WO-A1-2015/114164
WO-A1-2019/104442
 WO-A1-2016/144376
WO-A1-2019/135224
   
  • Vishal R. Patel ET AL: "Nanosuspension: An approach to enhance solubility of drugs", Journal of Advanced Pharmaceutical Technology & Research, 1 January 2011 (2011-01-01), pages 81-87, XP055090471, DOI: 10.4103/2231-4040.82950 Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pmc/articl es/PMC3217698/?report=printable [retrieved on 2013-11-27]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).